Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.21 and traded as low as $0.88. Eagle Pharmaceuticals shares last traded at $0.88, with a volume of 4,000 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Eagle Pharmaceuticals in a research note on Saturday. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Price Performance

The business’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.19.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. DGS Capital Management LLC increased its position in Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $96,000. RBF Capital LLC increased its holdings in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth $453,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.